Sign in to view content

Abicipar Pegol Phase 3 AMD Studies

Pravin U. Dugel, MD

Video
Published 2017

Related

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Does Anti-VEGF Therapy Affect the Rate of Expansion of Geographic Atrophy in Patients with Neovascular AMD Managed by a Treat-Extend-Stop Protocol?
Sean David Adrean, MD, FAAO, FASRS
On Demand Cases, Courses, and Papers
2019
A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more